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Abstract: Evidence is accumulating that tumour development is driven by cancer stem cells (CSCs).
In order to understand the presence and potential contribution of stem cells (SCs) as tumour-initiating
cells in canine cutaneous tumours, we selected three putative SC markers (Lgr5, Lgr6 and Sox9)
and investigated their expression pattern, level of protein and mRNA expression, in 43 canine hair
follicle (HF) and 18 canine cutaneous epidermal tumours by immunohistochemistry and qRT-PCR,
using normal skin samples as controls. Lgr5 protein expression was not detected in epidermal and
HF tumours; however, Lgr5 mRNA overexpression was evident in some HF tumours. Sox9 was
expressed in several tumour cases, both at the protein and mRNA level. The Lgr6 antibody tested
was not suitable for formalin-fixed paraffin-embedded tissue samples, but Lgr6 gene showed higher
expression in several samples of both HF and epidermal tumours compared with normal skin.
Significantly higher mRNA expression levels of the three SC markers were found in trichoblastomas
(TB) compared with basal cell carcinomas (BCC). The present results indicated that canine HF and
epidermal tumours might have common tumour-initiating cells. The mRNA expression of the three
selected SC markers, especially Lgr5, could be potentially useful in the distinction between canine TB
and BCC.
Keywords: cancer; dog; hair follicle; immunohistochemistry; qRT-PCR; skin; stem cell marker;
tumour-initiating cell
1. Introduction
A hierarchical organization of tumour cells has been proposed for most of the tumour types, based
on the existence of a specific population of tumour-initiating cells (TICs) with unlimited capacity for
self-renewal and proliferation. In the so-called TIC model, a specific neoplastic cell population exhibits
stem cell characteristics, having the ability to generate both, differentiated, highly proliferative tumour
cells as well as other self-renewing TICs that can regenerate all tumour cell types [1]. The term TICs is
often used interchangeably with “cancer stem cells” (CSCs). Recent findings demonstrated that CSCs
do not necessarily have to be rare and/or quiescent, but they can be abundant and proliferate actively.
A new concept has emerged in the last years about the active role of the stem cell niche in regulating
the hierarchical organization of tumour cells. Proliferation and quiescence of CSCs, like in normal stem
cells, are determined by signals derived from their niche, while the size of the niche itself determines
the number of stem cells [2]. Only cells that remain within the niche are stem cells, while those that
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leave the niche undergo differentiation into transient amplifying (TA) cells which in turn undergo final
differentiation. However, both the TA cells and differentiated cells can be reprogrammed into stem cells
by niche signals [2]. Interestingly, an inverse correlation between niche dependency and malignancy
has been observed. Tumour progression occurs through the acquisition of genetic alterations; as a
consequence, genetic variants render CSCs progressively independent of niche signals. The mutated,
independent CSC phenotype impedes differentiation, changing the tumour population with many
undifferentiated CSCs and a few non-CSCs [2]. This new CSC concept is in line with findings indicating
a correlation between the expression of stem cell (SC) markers and tumour progression, malignancy
and poor prognosis in many human and canine cancer types [3,4]. Indeed, CSCs/TICs express stem
cell markers, overexpress multidrug resistance molecules [5] and share several characteristics with
normal, adult SCs.
Permanently residing adult stem cells have been recognized in normal skin, and these are able
to sustain three principal differentiated lineages: the interfollicular epidermis (IFE), the sebaceous
glands (SGs) and the hair follicles (HFs), thus maintaining skin structure and integrity [6]. In canine
skin, several stem cell markers, including CD34, CK15, follistatin, CD200, Lgr5, Lgr6 and Sox9 [7–12],
have been investigated and demonstrated to have similar expression profiles as human and mouse HF
SC markers.
The exploration of biomarkers of canine skin cancer progression has been a long-standing focus
of our research group, both with the purpose of better understanding the biology of these tumours and
finding new potential therapeutic targets. We have previously demonstrated the overexpression of
several molecules known to be markers of TICs in canine epithelial skin tumours, such as β-catenin and
heat shock proteins (HSPs) [13,14], as well as the overexpression of several stem cells markers [15,16].
These findings suggest a potential implication of these molecules in the development, maintenance
and/or progression of canine skin tumours. A few other published studies focused on the examination
of selected putative stem cell markers to better classify canine cutaneous epithelial tumours and their
cell of origin [17,18]. However, the exact role of these cells as TICs in canine skin tumour development
and progression is not understood.
Based on a literature review, we selected three putative HF stem cell markers that have been
suggested as CSC markers in several tumour types, including skin tumours. The leucine-rich
repeat-containing G-protein-coupled receptors Lgr5 and Lgr6 are receptors involved in the Wnt
signalling pathway that have been identified as markers of stem cells in various tissues including
the intestine and the hair follicle [19]. Lgr5 marks actively cycling stem cells (SCs) and a multipotent
population in the hair follicle (HF). It maintains the cycling part of the HF and thus contributes to the
formation of all HF structures [20]. Lgr6 is a marker for distinct stem cells and is able to give rise to all
lineages of the skin (HF, sebaceous gland and interfollicular epidermis) [21]. Sox9 is a transcription
factor expressed in the sebaceous and sweat glands and the outer root sheath of the HF, as well as in
the bulge [22].
The aim of the present work was to evaluate the presence, immunostaining pattern and mRNA
expression level of selected putative stem cell markers (Sox9, Lgr5 and Lgr6) in a set of canine
cutaneous epithelial tumours. The investigated tumours included hair follicle tumours (trichoblastomas
(TB), trichoepitheliomas (TE), pilomatricomas (PM), infundibular keratinizing acanthomas (IKA),
trichilemmoma (TL)) and epidermal tumours (squamous cell carcinomas (SCC) and basal cell
carcinomas (BCC)). We expect that the result of this study on stem cell marker expression and
localization may aid to understand the contribution of TICs/CSCs in the development, maintenance
and progression of canine skin cancers. Since the selected SC markers are markers of canine hair
follicle stem cells [11] and are not expressed in the interfollicular epidermis in healthy skin conditions,
the present work also aimed to investigate whether a possible common cell of origin, residing within
the HF stem cell niche, contributes to the development of canine epidermal tumours (SCC and BCC).
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2. Material and Methods
2.1. Tumour Samples
Archival tissue samples of cutaneous epithelial tumours submitted to the biopsy service of the
Institute of Veterinary Pathology, Vetsuisse Faculty of the University of Bern, were used for this study.
Selection criteria were a definite histological diagnosis and good preservation of the samples. A total
of 52 canine skin tumours were selected and consisted of 37 hair follicle tumours, including benign
(8 TB, 5 TE, 4 PM, 7 IKA and 3 TL) and malignant (6 TE and 2 PM) forms, and 15 canine malignant
epidermal tumours (9 SCC and 6 BCC). As internal control, 3 samples of normal skin surrounding,
but distant to, the tumour mass were evaluated immunohistochemically and processed separately for
RNA isolation and subsequent qPCR analysis.
2.2. Histological Examination
All specimens were fixed in 10% neutral buffered formalin, embedded in paraffin, sectioned at 4–5
µm, stained with haematoxylin and eosin (H&E) and examined by light microscopy (Leica, DL-MS,
Wetzlar, Germany). Tumours were classified according to the World Health Organization criteria [23]
for canine cutaneous epithelial tumours and according to the classification of Gross et al. [24].
For each sample, the growth pattern (expansive or infiltrative growth), presence of necrosis, ulceration,
cellular/nuclear pleomorphism, inflammatory (lymphocytic/lymphoplasmacytic) infiltration and the
number of mitotic figures were evaluated as additional features. Malignancy was assessed considering
the mitotic index, cellular/nuclear pleomorphism, and infiltrative growth. Mitoses were evaluated
by counting the number of mitotic figures in 10 random, non-overlapping fields at the highest
magnification (HPF, 40×) in H&E stained slides.
2.3. Immunohistochemistry (IHC)
Sections were deparaffinized and rehydrated by passage through xylene and graded ethanol.
Immunohistochemistry was achieved using the following antibodies: rabbit polyclonal Lgr5
(HPA012530, Sigma-Aldrich, 1:1200, St. Louis, MO, USA), rabbit polyclonal Lgr6 (sc-99123, Santa Cruz
Biotechnology, different dilutions were tested from 1:50 to 1:1000, Dallas, TX, USA) and rabbit polyclonal
Sox9 (sc-20095, Santa Cruz Biotechnology, 1:250, Dallas, TX, USA). Antigen retrieval was carried out
in either sodium citrate buffer (self-made), pH 6.0, for 20 min at 80 ◦C (Lgr5) or in Tris-EDTA buffer
(self-made), pH 9.0, for 15 min in a pressure cooker (Sox9). Non-specific background was blocked
using 5% dried skim milk in phosphate-buffer saline (PBS). Subsequently, primary antibodies were
diluted in Dako REALTM Antibody Diluent (S2022, Dako, Baar, Switzerland) and applied for 60 min
at room temperature (Lgr5) or overnight at 4 ◦C (Sox9). The stained sections were further processed
according to the manufacturer’s instructions of EnVision+ Kits (Dako). 3-Amino-9-ethylcarbazole
(AEC) was applied as the chromogen (5–10 min). Tris-buffered saline (TBS; pH 7.6) (Sox9) or PBS
(Lgr5) (self-made) was used for the washing steps. All sections were counterstained with Ehrlich’s
haematoxylin. Separate sections were also incubated with equal concentrations of normal rabbit IgG
(sc-2027, Santa Cruz Biotechnology, Dallas, TX, USA) as negative controls. Immunohistochemical
protocols for Lgr5 and Sox9 were adapted from Gerhards et al. [11] and normal skin samples were used
as positive controls. For Lgr6 (sc-99123, Santa Cruz Biotechnology, Dallas, TX, USA), we performed
several experiments using both immunohistochemical and immunofluorescence techniques (as reported
in Supplementary File 1). As positive controls, human normal skin as well as canine trichoblastoma
cases (where a high mRNA expression level for Lgr6 was observed) were included.
2.4. Quantification of Immunolabelling
A semiquantitative immunohistochemical assessment was performed, considering nuclear
immunostaining in the entire tumour tissue (cross-section) for each case. Samples were subdivided
based on the protein expression levels in five ranges: absent, no positive cells; low, >0% to <10%
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positive cells; moderate, ≥10% to <25% positive cells; high, ≥25% to <50% positive cells; very high,
≥50% positive cells.
2.5. RNA Isolation and cDNA Synthesis
Three 20-µm-thick sections of each case were used for RNA extraction. Prior to RNA extraction,
the surrounding normal skin was cut off in order to ensure that only the gene expression of tumour
tissue is investigated. Three samples of normal skin were used as controls.
RNA extraction was performed according to the instructions for the use of the RNeasy Fibrous
Tissue Mini Kit (74704, Qiagen, Hombrechtikon, Switzerland). Concentrations were assessed using
a NanoDrop ND-1000 spectrophotometer. The synthesis of cDNA was carried out with reagents
from Promega AG (Dübendorf, Switzerland). In detail, the mixture contained 2 µL M-MLV Reverse
Transcriptase (M3682, Promega), 10 µL 5× Reaction Buffer, 2 µL RNasin Ribonuclease Inhibitor
(N2115, Promega), 2.5 µL dNTP Mix (U1515, Promega), 2.5 µL Random Primers (C1181, Promega),
11 µL H2O and 2 µg RNA dissolved in 20 µL H2O. Incubation was started at 25 ◦C for 10 min, followed
by 60 min at 42 ◦C, and was finished after 10 min at 95 ◦C. The cDNA was stored at –20 ◦C until use.
2.6. Quantitative Real-Time PCR
The amplification mixture contained 12.5 µL TaqMan Universal PCR Master Mix (4304437, Applied
Biosystems, Life Technologies, Zug, Switzerland), 2 µL of cDNA and 2.5 µL of 10 µM primers and
probes in a final reaction volume of 25 µL by the addition of RNase-free water. Primers are listed
in Table 1. Quantitative PCR was performed for 50 repeats on AB 7500 Fast Real-Time PCR System
(Applied Biosystems, Applied Biosystems, Life Technologies, Zug, Switzerland). Gene expression was
normalized to the level of ribosomal 18S and calculated based on the ∆∆CT method [25]. Reactions were
performed in triplicates and fold change expression was calculated for each gene using normal skin as
the reference.















SCC 9 5 0 3 1 0 5/9 absent
BCC 6 3 0 2 0 1 3/6 (50% of cases)absent
TL 3 1 1 1 0 0 variable (from absentto moderate)
IKA 9 2 2 3 1 1 5/9 moderate/low
TB 8 3 1 2 1 1 4/8 (50% of cases)absent/low
TE 11 5 4 1 1 0 9/11 absent/low
PM 6 1 3 1 0 1 4/6 absent/low
SCC: squamous cell carcinomas; BCC: basal cell carcinomas; TL: tricholemmomas; IKA: infundibular keratinizing
acanthomas; TB: trichoblastomas; TE: trichoepitheliomas; PM: pilomatrichomas.
2.7. Statistical Analysis
Fisher’s exact test was applied to evaluate the significance of the protein (Sox9) expression levels
and their correlation with histopathologically assessed malignancy. For this purpose, the cases were
grouped as follows: 0 (absent) versus >0 positive cells (from low to very high semiquantitative
evaluation). ANOVA tests were applied to compare the mRNA expression level of each marker in the
epidermal tumours with that of normal skin, as well as the HF tumours and normal skin. A two-tailed
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t-test was used to compare the mRNA expression levels between BCC and TB, and between benign
and malignant TE cases. The conventional 5% level was used to define statistical significance.
3. Results
All results, both from immunohistochemistry and RT-qPCR, are summarized in Supplementary
Table S2.
3.1. Stem Cell Marker Analyses in Healthy Skin. Sox9 and Lgr5 Protein Expression was Confirmed in Specific
Regions of Canine Hair Follicle
The presence of the mRNA of the three selected SC markers in canine skin was confirmed using
RT-qPCR. Ribosomal 18S was used as the reference gene.
Lgr6 protein was not detected immunohistochemically in normal control skin samples. Based on
our experiments and on the fact that the same antibody was previously confirmed to work on fresh
canine normal skin samples by western blot [11], we concluded that the applied anti-Lgr6 antibody
was not working on formalin-fixed paraffin-embedded tissue samples.
Lgr5 protein expression was immunohistochemically evident in the secondary germ of the telogen
and early anagen HF (Figure 1).
Figure 1. The localization of Lgr5 was confirmed in specific regions of canine hair follicle in healthy
skin. Lgr5 protein expression was immunohistochemically evident in the secondary germ of the telogen
and early anagen hair follicle (HF). Magnification 40×.
Sox9 immunostained cells were observed in the innermost cell (IMC) layer of the outer root
sheath (ORS) in the isthmus of late anagen hair follicles (Figure 2). Both markers did not stain
normal epidermis.
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Figure 2. The localization of Sox9 was confirmed in specific regions of canine hair follicle in healthy
skin. Sox9-positive cells in the innermost cell (IMC) layer of the outer root sheath (ORS) in the isthmus
of late anagen hair follicles. Magnification 20×.
3.2. Stem Cell Marker Analyses in Epidermal Tumours. Lgr5 and Sox9 are Downregulated Compared with
Normal Skin
Lgr6 mRNA was detected in both BCC and SCC, and appeared to be upregulated in most of the
BCC cases compared with normal skin and SCC. However, due to the high variation of the values,
the differences were not statistically significant (Figure 3).
Figure 3. Lgr5 and Sox9 are downregulated in epidermal tumours compared with normal skin. mRNA
expression of Sox9, Lgr5 and Lgr6 in normal skin and epidermal tumours. Bars represent mean ± SEM.
** p < 0.05; *** p < 0.001. Normal skin tissues (normal skin, n = 3), basal cell carcinomas (BCC, n = 6),
squamous cell carcinomas (SCC, n = 9).
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In contrast, the mRNA expression of both Lgr5 and Sox9 was significantly downregulated in these
tumours when compared with normal skin (Figure 3).
Lgr5 mRNA downregulation was statistically significant for the BCC samples, while protein
expression was not observed in any of the tumours analysed, confirming Lgr5 as a more specific HF
stem cell marker.
Sox9 mRNA expression was observed in both BCC and SCC, but it showed a significant
downregulation compared with normal skin. When the pattern of distribution of the protein was
analysed, about 50% of the cases of SCC (5/9) and BCC (3/6) showed positive cells (Table 1). In the
stained SCC samples, Sox9-positive cells were mainly present in the neoplastic cells showing basal cell
morphology (Figure 4), in infiltrating areas, and with a high level of expression (25–50% of positive
cells) in the specific SCC histotype known as basosquamous carcinoma (Figure 5). A patchy distribution
of immunostaining was observed in the positive BCC cases (Figure 6).
Figure 4. In SCC, Sox9-positive cells were mainly present in neoplastic cells showing basal cell
morphology. Magnification 40×.
Figure 5. In basosquamous SCC, high Sox9 expression was observed in tumour cells with basal cell
morphology, mainly in the inner parts of the neoplastic islands. Magnification 20×.
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Figure 6. In BCC, a patchy distribution of immunostaining was observed. Magnification 40×.
3.3. Stem Cell Marker Analyses in Hair Follicle Tumours. TB Samples Show the Highest mRNA Expression of
Lgr6, Lgr5 and Sox9, that are Potentially Useful Markers in Differential Diagnosis with BCC
Lgr6 mRNA was detected in all the HF tumour types, with the highest expression values in TB and TL
(inferior type). However, the expression varied significantly among the samples of the other HF tumour
types, reaching occasionally similar levels to the ones expressed in TB and TL samples (Figure 7).
Figure 7. TB samples show the highest stem cell marker mRNA expression levels. mRNA expression
of Sox9, Lgr5 and Lgr6 in normal skin and HF tumours. Bars represent mean ± SEM. No statistically
significant differences were observed comparing each tumour with normal skin. Normal skin tissues
(normal skin, n = 3), tricholemmomas (TL, n = 3), infundibular keratinizing acanthomas (IKA, n = 9),
trichoblastomas (TB, n = 8), trichoepitheliomas (TE, n = 11), pilomatricomas (PM, n = 6).
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Lgr5 mRNA expression was observed in all the HF tumours, with the highest levels in TB cases,
with an average fold change increase of 14 compared with normal skin. Very low mean levels of
Lgr5 gene expression, lower than that observed in normal skin, were recorded in TE and PM cases
(Figure 7). Immunohistochemistry showed that Lgr5 protein was absent in all HF tumour samples
analysed, despite the presence of positive immunostaining in the hair follicles of the skin surrounding
the tumour mass.
Sox9 mRNA expression was demonstrated in all tumour types analyzed, except for PM that
showed very low/absent levels of expression when compared with values obtained from normal skin
samples. The highest fold change was observed in TE and TB (Figure 7). The immunohistochemical
expression of Sox9 was observed in all tumour types analyzed, but with a different percentage of
positive cases and labelled neoplastic cells in the different groups (Table 1).
Sox9-positive cells were mainly present among the basaloid neoplastic cells of infundibular
keratinizing acanthoma (Figure 8). The immunolabelling was evident in the inner parts of the nests
of the TB, in both ribbon (Figure 9) and trabecular types, while only scattered positive nuclei were
evident in the TL samples (Figure 10). In the PM cases, neoplastic cells with matrical cell morphology
were negative; however, single or small clusters of positive cells were evident among these negative
matrical cells (Figure 11). A heterogeneous expression pattern based on the predominant hair follicle
differentiation was observed in TE samples (Figure 12), with no difference between the benign and
malignant forms.
Figure 8. In IKA, Sox9-positive cells mainly present among the neoplastic cells of the basal cell layer of
the tumour wall. Magnification 20×.
When levels of mRNA expression of Sox9, Lgr5 and Lgr6 were compared between TB and BCC,
statistically significant differences were observed for all the three markers, with higher expression
levels in TB cases (p < 0.001).
In order to understand if the investigated HF stem cell markers could have a potential role
as prognostic markers in these types of skin tumours of the dog, differences between benign and
malignant tumours were analysed for both protein and mRNA expression. However, the majority of
the malignant tumours included in the present work were epidermal tumours, resulting in bias in the
distribution of malignant tumours in our case series. So, we limited the comparison to the TE group.
A tendency towards an increase of Sox9 and Lgr6 mRNA expression in malignant TE was observed
compared with benign cases (Figure 13).
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Figure 9. TB, ribbon type: positive neoplastic cells in the inner parts of the tumour nests. Magnification 40×.
Figure 10. TL, inferior type: scattered, positive nuclei evident in the neoplastic islands. Magnification 40×.
Figure 11. PM: negative neoplastic cells with matrical cell morphology associated with single or small
clusters of positive cells. Magnification 40×.
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Figure 12. TE: groups of positive neoplastic cells within the parts of the tumour with basal cell
morphology. Negative cells with squamous differentiation. Magnification 40×.
Figure 13. Sox9 and Lgr6 mRNA are potential markers of malignancy in TE tumours. mRNA expression
of Sox9, Lgr5 and Lgr6 in TE cases. When the average values of benign and malignant cases were
compared within the TE group, differences were present for all the three markers. Two-tailed t-test:
Sox9, not significant (n.s.) (p = 0.379); Lgr5, n.s. (p = 0.269); Lgr6, n.s. (p = 0.150).
4. Discussion
In the present work, we investigated the expression of three putative HF stem cell markers in
cutaneous epithelial tumours of dogs. Stem cell marker expression in neoplastic cells could have
different meanings. They mark cancer stem cells that (a) can originate from tumour cells derived from
the HF SCs and can represent the tumour cell of origin or (b) are neoplastic dedifferentiated cells that
have acquired new stemness properties. Conditions (a) and (b) appear to be different, even opposite.
However, based on new concepts of CSC plasticity and stem cell niche [2], we cannot exclude the
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possibility that the two situations can be simultaneously present in the heterogeneous population of
a tumour.
Interestingly, Lgr6 gene was highly expressed in the epidermal tumours analysed. It has been
shown in mice, that Lgr6 protein expression is located in the stem cell niche above the bulge; this protein
is considered as a marker of HF stem cells that are able to give rise to all lineages of the skin (HF,
sebaceous gland and interfollicular epidermis), and to contribute to wound healing. In line with
this, Lgr6 was expressed in both HF and epidermal skin tumours of our study, indicating a potential
common cell of origin of these tumours, that are then able to differentiate into different lineages.
In accordance with our findings, Lgr6 was identified as an epithelial stem cell marker in mouse SCCs,
as well [26]. This would suggest that, in dogs, similar to what has been hypothesized in human [27],
the cell of origin of these epidermal tumours can be represented by: an interfollicular epidermal stem
cell, re-expressing hair follicle stem cell markers; an hair follicle stem cell; or even a differentiated
tumour cell that can be reprogrammed and expresses HF stem cell markers.
Lgr5 is a more specific HF stem cell marker compared with Lgr6 and Sox9, that is able to regenerate
the cycling part of the HF and give rise to only the different HF structures, under normal conditions.
Compatible with this is that its mRNA expression was observed only in HF tumours, but not in SCC
and BCC. This is in line with previous studies on human SCC, where Lgr5 protein expression was
not observed either [26]. In mice, however, in a specific skin condition determined in Lgr6 germline
KO mice, Lgr5 gene expression could be upregulated in a compensatory mechanism, contributing to
the development of cutaneous SCC [26,28]. Despite the high mRNA expression levels of all three
SC markers, no immunolabelling was observed in any of the HF tumours investigated. Since the
surrounding HFs were positively labelled by the antibodies, we have to conclude that the protein
expression in the tumour is very low. This might be the consequence of post-translational regulation
mechanisms, resulting in protein expression which is too low to be detectable with the applied
immunohistochemical technique.
The immunohistochemical expression pattern of Sox9 in canine normal HFs, as already previously
reported by Gerhards et al. [11], would confirm it as a marker of stem cells already committed to
ORS differentiation, as in human HFs [29]. We observed a Sox9-positive cell subpopulation in both
epidermal and HF tumours, confirming results reported by Fantinato et al. [17]. Our results would
indicate, in some canine HF tumours, such as IKA, TE and TB, as well as in SCC and BCC, the presence
of ORS differentiation and/or a potential role of these cells in the development of these tumour types.
These results are in agreement with previous results reported in humans, where Sox9 protein was
expressed in BCC samples, as well as in TE and TL, indicating Sox9 as a general feature of differentiation
of these types of tumours [30]. In our cases, as in humans [30], Sox9 immunostaining was almost
completely restricted to tumour cells with basal cell-like morphology, and this was particularly evident
in IKA and SCC positive cases.
Both Lgr5 and Lgr6, together with the other member of the same receptor family, namely Lgr4,
are recognized mediators of the Wnt signalling pathway, that is activated in human HF tumours,
especially TB [31], and probably in canine TB as well, as indicated by the presence of numerous positive
nuclei [14]. In accordance with that, both Lgr5 and Lgr6 showed the highest mRNA expression levels in
this tumour type in dogs (present results) and humans [19]. In both species, it is sometimes difficult to
differentiate between BCC (epidermal origin) and TB (follicular origin) histologically, and a common
origin of the two neoplasms has also been discussed [24]. Indeed, both neoplasms are composed of
basaloid cells, with overlapping histopathological features [24,32]. This problem has been specifically
addressed in numerous human published studies. Although some markers (such as AR, CK20 and
PHLDA1) have been proposed as useful in distinguishing BCC from benign, hair-germ tumours
(such as TB), no single marker seems to be completely sensitive or specific for this distinction [33].
The expression pattern of Sox9 has also been used to reiterate the follicular origin of human BCC
by some authors [30,34]. Indeed, Sox9 expression, together with the cytokeratin profile of human
BCC [35], would suggest a differentiation of these tumours along the ORS [34]. Comparable results
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on canine BCC obtained in the present study would also suggest a differentiation of some BCC cells
along the ORS, similar to what we found in TB. However, recent results in dogs demonstrated a
different cytokeratin (CK) and stem cell marker expression pattern profile in the two tumours: the
basal cell markers p63 and CK14 were diffusely expressed in BCC, while TB tumours were strongly
positive for CK8 and CD34, CK15 and CK19 [18]. Besides that, in the present study we observed
statistically significant differences in the levels of mRNA expression of the three selected SC markers
in the two tumours, suggesting their (in particular, Lgr5) use as potential markers in the distinction
between BCC and TB. Taken together, the data would suggest that different neoplastic (stem cell)
populations could be involved in the development/maintenance of these two neoplasms. However,
it still remains unknown if the expression of these markers would indicate that the two tumours
recognize different TICs, or if their neoplastic cells could dedifferentiate and acquire different stem cell
marker expression. One possible hypothesis for human BCC [36] considered that adult interfollicular
tumour-initiating/stem cells are reprogrammed into an embryonic hair follicle progenitor-like fate
during BCC initiation. However, based on different experimental conditions, several adult somatic or
stem cells of the skin can participate in tumour initiation [27], rendering difficult to understand the
in vivo mechanisms of skin cancer development.
We tried to investigate a possible role of the selected stem cell markers in cancer progression and
their potential relation with histologically assessed tumour malignancy. Although differences were
not significant, a trend towards upregulation of Sox9 and Lgr6 mRNA expression in malignant TE
compared with benign ones was observed. This is in accordance with our previous studies on Sox9
immunohistochemical expression in different canine tumours types [4], including sebaceous gland
tumours [37]. However, further studies should be performed to confirm the suggested potential role of
Sox9 and Lgr6, both at the protein and mRNA level, as cancer markers of malignancy.
5. Conclusions
In conclusion, we confirmed the expression of some putative HF stem cell markers in epidermal
canine skin tumours, namely SCC and BCC, in the present study. Furthermore, we propose that the
evaluation of these HF SC markers, and more specifically Lgr5 mRNA expression, could be useful to
determine the final diagnosis in ambiguous cases between TB and BCC. However, a future study on a
larger case series is needed to further evaluate the discriminatory potential of Lgr5. Lastly, Lgr6 and
Sox9 mRNA appeared to be more expressed in malignant forms of specific tumour types (TE), indicating
a potential role of the two molecules in cancer progression and as prognostic markers.
The present study, together with previous published work, indicate that the wide range of
histomorphological differentiation of canine skin tumours is related to the heterogeneous stem cell
population present in the skin, that could play the role of TICs, and to the tight communication of these
cells with their niche. Understanding how normal/cancer stem cells are regulated and communicate
with cells of the microenvironment, thus contributing to cancer development and/or progression and
drug resistance mechanisms, will represent the future steps in this field of research.
Supplementary Materials: The following are available online at http://www.mdpi.com/2306-7381/7/2/62/s1,
Table S1: RT-qPCR primers and probes, Table S2: Summary of the results obtained by IHC, RT-qPCR and
histological analysis of the samples;
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